Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy

Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients undergoing cancer chemotherapy, especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Chih-An, Chen, Wen-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316946/
https://www.ncbi.nlm.nih.gov/pubmed/34368296
http://dx.doi.org/10.12998/wjcc.v9.i21.5769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316946/
https://www.ncbi.nlm.nih.gov/pubmed/34368296
http://dx.doi.org/10.12998/wjcc.v9.i21.5769

Ejemplares similares